- AdventHealth
The Obesity Society awarded Steven R. Smith, M.D., chief scientific officer and senior vice president of AdventHealth, the TOPS Research Achievement Award for his research on obesity, diabetes and the metabolic origins of cardiovascular disease.
Smith is one of 15 clinicians recognized by the international professional society.
Made possible through an annual grant from the Take Off Pounds Sensibly (TOPS) Foundation, the TOPS Research Achievement Award recognizes one distinguished scientist for a singular achievement or contribution to research in the field of obesity.
At the AdventHealth Translational Research Institute, Smith and his colleagues are currently investigating the reasons people develop obesity, particularly abdominal adiposity.
“We’re working on how genes can be programmed in the womb or during development to influence where fat is stored, either in the abdomen or in the hips and thighs,” he said. “The epigenomic programming of adipose tissue has the potential to not only help develop obesity treatments, but to also prevent the downstream metabolic diseases like diabetes, cancer and heart disease that occur in people with abdominal obesity – diseases that are lower in people with a predisposition to store fat below the waist.”
In addition, Smith is specifically focused on understanding how individuals differ in their ability to adapt to diets high in fat and how obesity leads to Type 2 diabetes.
Using the translational medicine approach, he along with the AdventHealth Translational Research team discovered that many obese people have an inability to burn fat and a new hormonal control system to increase fat and energy metabolism. Most importantly, the team’s discovery that the inability to burn fat is programmed into muscle cells provides a novel way to identify and test new treatments for obesity and diabetes.
“The world of research inspires me to find better solutions for patients,” said Smith. “We’ve just finished an exciting study – set to be published in the coming months – that helps us understand how the gut microbiome affects energy balance. We believe this will change the way our colleagues think about the prevention of weight gain across the lifespan and help people lose weight and keep it off.”
In early 2022, Smith assumed the role of chief scientific officer, where he provides scientific as well as research oversight and operational leadership across AdventHealth’s nearly 50 hospitals in nine states.
“The Obesity Society is honored to recognize Dr. Smith for his many contributions to our understanding of the roles that dysfunction in adipose tissue and skeletal muscle play in the development of obesity and Type 2 diabetes,” said Dan Bessesen, M.D., president of The Obesity Society. “He has been a leader in obesity research for many years and continues to make fundamental scientific contributions which aim to help improve the health of people with obesity.”
Over the course of his career, Smith has contributed to over 200 peer-reviewed publications, including scientific manuscripts, reviews and chapters. He has also served as president of The Obesity Society and has been a long-time advocate for persons affected by obesity.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...
AdventHealth Research Institute and NESTRE Health & Performance Announce Collaboration to Advance Neurocognitive Health and Performance Through Cognitive Training
With an aging population and increases in the prevalence of neurological conditions like Alzheimer’s disease and dementia, physicians and patients alike continue to seek new tools and approaches to...
AdventHealth Among First in U.S. to Offer IDP023-2-101 Clinical Trial for Patients with Progressive Multiple Sclerosis
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple...